SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-019857
Filing Date
2022-05-12
Accepted
2022-05-12 16:09:40
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20220512.htm   iXBRL 8-K 35507
2 EX-99.1 achv-ex991_6.htm EX-99.1 168505
3 GRAPHIC gcewk2ereahd000001.jpg GRAPHIC 18627
  Complete submission text file 0001564590-22-019857.txt   372877

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA achv-20220512.xsd EX-101.SCH 5617
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20220512_lab.xml EX-101.LAB 20039
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20220512_pre.xml EX-101.PRE 11943
8 EXTRACTED XBRL INSTANCE DOCUMENT achv-8k_20220512_htm.xml XML 3674
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 22917857
SIC: 2835 In Vitro & In Vivo Diagnostic Substances